Corporate reputation in the age of GLP-1 Podcast Por  arte de portada

Corporate reputation in the age of GLP-1

Corporate reputation in the age of GLP-1

Escúchala gratis

Ver detalles del espectáculo

Obtén 3 meses por US$0.99 al mes

Listen to Thomas Fife-Schaw and Nick Gabery Adams, former VP of Corporate Brand at Novo Nordisk, discuss how GLP-1 medications like Ozempic and Wegovy are changing the pharmaceutical landscape. From reshaping corporate reputation, to boosting investor confidence, discover how these drugs are rewriting the rules for pharma brands.

Todavía no hay opiniones